Internal Medicine

Analysis shows that biosimilar uptake was up to 2-fold greater in Medicare Advantage coverage than traditional Medicare.

The current treatment paradigm might need to evolve to adjust to rapid diagnostics and narrowing down the antibiotics to aid in optimal outcomes for sicker patients with gram-negative infections.

Data from a nationally representative survey show that, despite most US adults agree the COVID-19 and flu vaccines are safe and effective, there is discrepancy in why some may not want one or the other.

Clinicians and investigators alike navigate waning protection against the complex disease to push precedent-setting research and identify new care options.

Despite a boom of new, cost-efficient options for chronic conditions, prescriber and patient concern over clinical benefit persists.

Califf joins HCPLive to share perspective on AI, gene and cell therapy development, COVID-19, food and substance regulation, maternal and infant health, weight loss intervention, and more.

The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery.

Analysis shows the rate of use with the originator biologic has decreased from 90% in 2016, to 19% in 2021.

A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.

Elevated serum endotrophin levels, but not urinary endotrophin levels, predict increased risk of kidney complications and mortality in type 1 diabetes.

In their latest recommendation statement, the USPSTF recommends blood pressure screening for all pregnant individuals to detect hypertensive disorders.

Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.

New phase 2 study findings link levosulpiride treatment for 8 weeks with improved visual and structural outcomes and no significant adverse side effects.

A program from the American Oncology Network shows promise to introducing cost-efficient biosimilar substitution opportunities to prescribers and payors.

An analysis of ophthalmology subspecialty fellowships in 2021 revealed a lower match rate for applicants considered underrepresented in medicine.

In the latest episode of Lungcast, the diagnosis, classifciation and treatment of PE—namely blood clots—is comprehensively dissected by the Lewis Katz School of Medicine clinician and investigator.

An analysis of life expectancy growth since the 1930s suggest more than 50 countries have surpassed the US—with the gap compared to the leading countries widening in that time.

The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.

An analysis of data from more than 30,000 people with type 2 diabetes provides insight into the long-term use of metformin and risk of vitamin B12 deficiency.

An analysis of data from CREDENCE provides insight into the prognostic potential of a group of 4 common biomarkers for predicting cardiovascular and kidney issues in people with type 2 diabetes.

The adjusted odds of vision testing decreased by 41% for uninsured and 24% for publicly insured participants versus those with private insurance.

In their latest column, Kim Zuber, PA-C, and Jane Davis, DNP, break down the concept of "sick day rules" and what this means for providers caring for those with kidney disease.

In a Q&A, Clipper Young, PharmD, MPH, discusses the Pharm2Home Initiative based on his presentation from ADCES 2023 and describes the impact of community-driven, pharmacist-led interventions to improve health literacy in those with chronic disease.

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

At ADCES 2023, Halis Akturk, MD, presented data calling attention to the risk of hyperglycemic ketosis-cannabis hyperemesis syndrome in people with type 1 diabetes.